Primary focus is patent prosecution, strategic counseling, IP due diligence, drug and medical device FDA regulatory counseling, invalidity and non-infringement opinions, Supreme Court and Federal Circuit amicus briefs. Has obtained patents for companies which have been sold for a cumulative total of approximately $4 billion. Prosecuted patents covering three FDA approved drugs. Authored numerous freedom-to-operate, invalidity, and non-infringement opinions, including opinions supporting paragraph IV certification for ANDA filers under the Hatch-Waxman Act. Advised companies on the use of post-grant U.S. Patent and Trademark Office proceedings to achieve IP goals.